HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 47, 34356-34364, November 23, 2007

This Article Abstract Full Text (PDF) Supplemental Data All Versions of this Article: 282/47/34356    most recent M706644200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Social Bookmarking                      What's this?

The Direct Involvement of SirT1 in Insulin-induced Insulin Receptor Substrate-2 Tyrosine Phosphorylation^*

From the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas Texas 75390

Received for publication, August 9, 2007 , and in revised form, September 19, 2007.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
NAD⁺-dependent Sir2 family deacetylases and insulin signaling pathway are both conserved across species to regulate aging process. The interplay between these two genetic programs is investigated in this study. Protein deacetylase activity of SirT1, the mammalian homologue of Sir2, was suppressed through either nicotinamide treatment or RNA interference in several cell lines, and these cells displayed impaired insulin responses. Suppression of SirT1 activity also selectively inhibited insulin-induced tyrosine phosphorylation of insulin receptor substrate 2 (IRS-2), whereas it had minimal effect on that of IRS-1. Further analyses showed that both IRS-1 and IRS-2 interacted with SirT1, and the acetylation level of IRS-2 was down-regulated by insulin treatment. Inhibition of SirT1 activity prevented deacetylation and insulin-induced tyrosine phosphorylation of IRS-2. Mutations of four lysine residues to alanine in IRS-2 protein, on the other hand, led to its reduced basal level acetylation and insulin-induced tyrosine phosphorylation. These results suggest a possible regulatory effect of SirT1 on insulin-induced tyrosine phosphorylation of IRS-2, a vital step in insulin signaling pathway, through deacetylation of IRS-2 protein. More importantly, this study may imply a pathway through which Sir2 family protein deacetylases and insulin signaling pathway jointly regulate various metabolic processes, including aging and diabetes.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Calorie restriction, the only physiological method known so far to extend lifespan in animals ranging from Caenorhabditis elegans to mammals, is associated with global metabolic changes, including reduced insulin level, increased gluconeogenesis, and reduced lipid metabolism. The identification of Sir2 as the mediator of calorie restriction on lifespan regulation is a major breakthrough in understanding the molecular mechanism underlying the aging process (1, 2).

Sir2 and its mammalian counterpart, SirT1, belong to a family of NAD⁺-dependent protein deacetylases. Sir2 is actively involved in lifespan regulation in C. elegans, yeast, and Drosophila. Disruption of Sir2 gene leads to a reduced lifespan, whereas overexpression of Sir2 leads to significant lifespan extension in these species (2). In the mammalian system, SirT1 has been involved in multiple metabolic processes including glucose homeostasis (3), insulin secretion (4, 5), and lipid mobilization (6). However, its role in lifespan regulation remains ambiguous.

Insulin signaling pathway is also actively involved in the aging process (7). As a critical component of overall energy homeostasis, insulin signaling pathway has been well studied, and the key steps have been characterized (8). Insulin signaling pathway is initiated by auto tyrosine phosphorylation of insulin receptor upon insulin binding, and subsequently tyrosine phosphorylations of several key adaptor proteins including insulin receptor substrate 1 (IRS-1)² and IRS-2. The phosphorylated IRS proteins further transmit insulin signaling to downstream events, mainly through two kinase cascades, the mitogen-activated protein kinase cascade (MAPK) and phosphatidylinositol 3-kinase-Akt cascade.

Genetic studies using C. elegans as a model system demonstrate a tight connection between insulin signaling pathway and aging. Mutations at several key components of insulin signaling pathway, including daf-2 (Insulin receptor), Age-1 (phosphatidylinositol 3-kinase), and daf-16 (Foxo proteins), all significantly extend the lifespan of C. elegans (7). Likewise, inactivation of insulin receptor in adipose tissue leads to extended lifespan in mice (9), and deletion of Klotho, a protein potently inactivating insulin receptor activity in cell culture studies, accelerates aging process in mutant mice (10). In this laboratory resveratrol, a chemical compound known to extend lifespan in several species including C. elegans, yeast, and Drosophila, has also been demonstrated to inhibit insulin signaling pathway in cell culture studies (11). These observations support a vital role of insulin signaling pathway in aging process.

The associations of both the insulin signaling pathway and the Sir2 family protein deacetylases with the aging process raise an important question; do these two pathways independently or jointly regulate aging process? In other words, is there any direct association between these two pathways? This question is explored in this study, and the results provide direct evidence supporting a novel role of SirT1 in regulating insulin-signaling pathway in mammalian cells.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
General Reagents—Various cell culture reagents, including Dulbecco's modified Eagle's medium, M199 medium, penicillin/streptomycin, and fetal bovine serum were obtained from Fisher. Insulin was obtained from Sigma. Antibodies against p44/42 MAPK, phospho-AKT (serine 473 and threonine 308), AKT, and acetylated lysine polyclonal antibodies were obtained from Cell Signaling Technology (Beverly, MA). Monoclone FLAG antibody (M2) and phospho-p44/42 MAPK monoclonal antibody were obtained from Sigma. Anti-acetyl lysine 4G12 and anti-phosphotyrosine 4G10 antibodies were obtained from Millipore (Lake Placid, NY). Antibodies against insulin receptor , retinoblastoma, were obtained from BD Biosciences. Antibodies against SirT1, cAMP-responsive element-binding protein-1, IRS-1, IRS-2, normal mouse IgG, normal rabbit IgG, and protein A/G plus beads were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Cell Culture—H4IIE, HEK293 cells, were maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. Rat primary hepatocytes were isolated as described previously (11) and set up in M199 medium supplemented with 100 nM dexamethasone, 100 nM triiodothyronine, and1nM insulin overnight before they were changed into M199 medium supplemented with 100 nM dexamethasone for further treatments.

Cell Fractionation—HEK293 cells were seeded at 3 x 10⁶/100-mm dish, and grew in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum for 2 days. Cells were serum-starved overnight, and 3 dishes of cells were pooled together and resuspended in 0.2 ml of hypotonic buffer A (10 mM Hepes-KOH, pH 7.4, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose supplemented with protease inhibitors) and passed through a 22.5-gauge needle 15 times before they were centrifuged at 1000 x g for 7 min at 4 °C. The 1000 x g pellet was resuspended in 0.1 ml of buffer B (20 mM Hepes-KOH, pH 7.4, 2.5% glycerol, 0.42 M NaCl, 1.5 mM MgCl₂ supplemented with protease inhibitors), rotated at 4 °C for 1 h, and centrifuged at 1 x 10⁵ x g for 30 min in a Beckman TLA 100.2 rotor. The resulted supernatant was designated as the nuclear fraction. In the meantime, the supernatant from original 1000 x g centrifugation was re-centrifuged at 8000 x g in a microcentrifuge for 15 min, and the resulted supernatant is designated as the cytosolic fraction. The 8000 x g pellet was resuspended in 100 µl of buffer A and was designated as the membrane fraction.

Plasmid Construction—Full-length IRS-1 and IRS-2 cDNAs were PCR-amplified from mouse cDNA derived from mouse liver total RNA. PCR products were verified by DNA sequencing and inserted into a pcDNA 3.1(+) plasmid. Three tandem copies of FLAG epitope were inserted into mouse IRS-1 or IRS-2 N-terminal sequence. Mouse SirT1 cDNA was obtained from Millipore, and five tandem copies of Myc epitope were inserted into SirT1 C-terminal sequence. For construction of constitutive expressed RNA interference (RNAi) constructs, RNAi-Ready pSIREN-RetroQ plasmid from Clontech was used by following the manufacturer's instructions using a targeting sequence against SirT1 (pSIREN-SirT1) or against luciferase, pSIREN-Luciferase (11). FLAG-IRS-2 deletion mutants were created using the QuikChange site-directed mutagenesis kit from Stratagene by using primers joining the flanking sequences of the both end of the deleted sequence using FLAG-IRS-2 construct as template. For creation of FLAG-IRS-2 (K4A) mutants, three rounds of site-directed mutagenesis were conducted using the QuikChange site-directed mutagenesis kit by first creating k289A/k292A double mutant using FLAG-IRS-2 construct as template. The double mutant was used as a template next to create triple mutant K289A/K292A/K412A mutant, and finally the triple mutant was used as template to create K289A/K292A/K412A/K118A mutant.

Immunoprecipitation and Western Blot Analysis—For H4IIE cells, cells were seeded at 2 x 10⁶/60 mm dish for 1 day and serum-starved overnight before they were treated with various agents, as indicated in the figure legends. For HEK293 cells, these cells were set up at 0.6 x 10⁶/60-mm dishes and transfected with plasmid DNA for 48 h using FuGENE 6 transfection regents. Cells were serum-starved overnight before they were treated with various agents, as indicated in the figure legends. After treatment, cells were harvested and lysed in lysis buffer (50 mM Hepes, pH 7.4, 137 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1 mM MgCl₂, 10 mM Na₂P₂O₇, 1% Triton X-100, 10% glycerol) supplemented with protease and phosphatase inhibitors (100 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride, 5 µg/ml pepstatin, 10 µg/ml leupeptin, 5 µg/ml aprotinin) by pipetting up and down 50 times. Supernatants were collected after 5 min of microcentrifugation at 8000 x g for Western blot analysis. For immunoprecipitation, equal amount of cell lysates were preincubated with protein A/G plus beads for 30 min at 4 °C under constant agitation, and the resulting supernatants were transferred into fresh tubes and incubated with primary antibody for another hour followed by the addition of 60 µl of protein A/G plus beads for an additional 1 h. Protein A/G plus beads were collected at 1000 x g for 1 min using microcentrifugation, washed several times with lysis buffer, and subjected to Western blot analysis. For Western blot analysis, immunoprecipitates or total cell lysates were resuspended in sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol supplemented with bromphenol blue) and heated for 5 min at 75 °C. Proteins were separated using SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting.

Northern Blot Analysis—Total RNA was extracted using TRIzol reagent from Invitrogen following the manufacturer's instructions. An equal amount of RNA was resuspended into RNA loading buffer (Sigma), separated by 1% agarose-formaldehyde gel, and transferred to a nylon membrane (Hybond-N⁺). The cDNA probes were labeled with [-³²P]dCTP using a random primer labeling kit from Amersham Biosciences. Hybridization was performed at 65 °C in ExpressHyb hybridization solution (BD Biosciences Clontech) according to the manufacturer's instructions. Membranes were exposed to x-ray film at either room temperature or -80 °C for 16 h.

Establishing Stable Cell Lines—H4IIE cells were transfected with 0.1 µg/100-mm dish pSIREN-RetroQ plasmid constitutively producing small interfering RNA against either luciferase (pSIREN-Luciferase) or the SirT1 coding sequence (pSIREN-SirT1) using FuGENE 6 transfection reagent for 48 h. Stable clones were isolated by puromycin selection at 6 µg/ml. The stable clones were isolated based on Northern blot analysis using specific probe against SirT1. For establishing HEK293 stable clones, cells were transfected with pSIREN-Luciferase or pSIREN-SirT1 for 48 h using FuGENE 6 transfection reagent, and stable clones were isolated using puromycin selection at 1 µg/ml. The stable clones were isolated based on Western blot analysis using SirT1 antibody from Santa Cruz.

In Vitro Deacetylation—HEK293 cells were transfected with 0.5 µg/60-mm dish FLAG-IRS-2 construct using FuGENE 6 reagent according to the manufacturer's instructions. After 48 h, cells were serum-starved overnight before total cell lysates were prepared for immunoprecipitation using anti-FLAG antibody. Meanwhile, untransfected HEK293 cells were also serum-starved overnight and treated with insulin for 10 min. Endogenous SirT1 protein was immunoprecipitated using rabbit anti-SirT1 antibody from total cell lysates and washed several times in the lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM EDTA, and 0.4% Triton X-100). The immunoprecipitated agarose beads were separated into deacetylation buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 4 mM MgCl₂, 10% glycerol, and 1 mM dithiothreitol), treated with and without -NAD⁺, and incubated for 2 h at 37 °C. Total samples were quickly spun using a microcentrifuge and resuspended in sample buffer for Western blot analysis.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Several small chemical compounds, including nicotinamide and splitomycin, have been demonstrated to potently inhibit protein deacetylase activity of SirT1 (12). These compounds were first used to treat H4IIE cells to investigate their effects on insulin-induced MAPK and Akt activations (Fig. 1A). Insulin treatment alone induced strong Akt activation, demonstrated here by phosphorylations at both threonine 308 and serine 473 sites of Akt protein. Coincubation of either nicotinamide at 6 mM or splitomycin at 100 µM for 6 h significantly inhibited insulin-induced Akt phosphorylations at both sites. However, under the same condition, these compounds had minimal effects on insulin-induced MAPK activation, demonstrated here by phosphorylations of p42/p44 extracellular signal-regulated kinase (ERK) proteins.

A dose response study of the nicotinamide effect on insulin-induced MAPK and Akt activations was shown in Fig. 1B. Cells were treated with nicotinamide ranging from 0.3 to 10 mM for 6 h, and Western blot analysis showed that although MAPK activation was not affected by nicotinamide treatment at all, insulin-induced Akt activation was slightly inhibited with 3 mM nicotinamide and significantly inhibited with 10 mM nicotinamide. To rule out the possibility that these results were due to cell line specificity, similar experiments were also conducted using rat primary hepatocytes (Fig. 1C) and HeLa cells (data not shown). In these cells nicotinamide significantly inhibited insulin-induced Akt activation but had minimal impact on insulin-induced MAPK activation.

The nicotinamide effect on the insulin regulation of downstream target gene expressions at the transcriptional level was also investigated (Fig. 1D). Consistent with what was observed in SirT1 null cells (13), nicotinamide treatment led to a significantly increased mRNA level of phosphoenolpyruvate carboxykinase at the basal state but had little effect on the suppressive effect of insulin on phosphoenolpyruvate carboxykinase expression. Nicotinamide treatment also clearly suppressed insulin-induced up-regulation of fatty acid synthase mRNA level. The mRNA level of cyclophilin was measured as the loading control in this experiment. These results suggest that inhibition of SirT1 activity directly interferes with insulin signaling pathway at both protein and mRNA levels.

View larger version (38K): [in this window] [in a new window]   FIGURE 1. Inhibition of SirT1 activity leads to impaired insulin responses. A, SirT1 inhibitors inhibited insulin-induced Akt phosphorylation. H4IIE cells were serum-starved overnight and treated with or without either nicotinamide (NAM, 6 mM) or splitomycin (Splito, 100 µM) for 6 h before they were treated with 100 nM insulin for 10 min. Equal amount of total cell lysates were used for Western blot analysis using antibodies against phosphorylated (p-) forms of MAPK, total MAPK, phosphorylated Akt at the Thr-308 site, phosphorylated Akt at the Ser-473 site, and total Akt. B, dose response study. H4IIE cells were serum-starved overnight and coincubated with increased dose of nicotinamide ranging from 0.3 to 10 mM for 6 h. Cells were treated with and without 100 nM insulin for 10 min, and equal amounts of total cell lysates were used for Western blot analysis using antibodies against the phosphorylated forms of MAPK, total MAPK, phosphorylated Akt at Ser 473 site, and Akt. C, nicotinamide inhibited AKT activation in rat primary hepatocytes. Rat primary hepatocytes were isolated and seeded at 2 x 106/60-mm collagen-coated dish as described elsewhere (11). Cells were pretreated with 6 mM nicotinamide for 4 h and treated with and without insulin (100 nM) for another 10 min before total cell lysates were prepared for Western blot analysis using antibodies against phosphorylated forms of MAPK, total MAPK, phosphorylated Akt at Ser-473 site, and Akt. D, nicotinamide treatment interfered with insulin signaling pathway at mRNA level. Rat primary hepatocytes were setup as described in C and treated with nicotinamide (6 mM) and insulin (100 nM) for 6 h as indicated in the figure. Total mRNA was extracted and used for Northern blot analysis using probes against phosphoenolpyruvate carboxykinase (PEPCK), fatty acid synthase (FAS), and cyclophilin. All experiments have been conducted at least three times.

View larger version (16K): [in this window] [in a new window]   FIGURE 2. Reduced SirT1 expression level by RNAi technique is associated with reduced insulin-induced Akt activation. H4IIE cells carrying the pSIREN-RetroQ plasmid producing small interfering RNA against either luciferase (pSIREN-Luciferase) or SirT1 (pSIREN-SirT1) were isolated as described under "Experimental Procedures." Clone Luc is derived from cells transfected with pSIREN-Luciferase, whereas clones 1 and 2 are derived from cells transfected with pSIREN-SirT1. A, clone Luc, 1 and 2, were serum-starved overnight and treated with and without 100 nM insulin for 10 min. Equal amounts of total cell extracts were used for Western blot analysis using antibodies against phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK-1/2), total extracellular signal-regulated kinase, phosphorylated Akt at serine 473 site, and total Akt protein. The result was quantified using ImageJ program (http://rsb.info.nih.gov/ij), and the results are the average of three independent experiments and are expressed as the ratio between phosphorylated protein over total proteins. The relative levels of extracellular signal-regulated kinase 1/2 and Akt of clone Luc were set as 1. Statistical analysis was conducted using paired student t test. *, p < 0.05. B, total RNA was extracted from clone Luc, 1 and 2, using TRIzol reagent. Equal amounts of total RNA (16 µg/lane) were used for Northern blot analysis using probes against SirT1 and cyclophilin. Results are representatives of three similar experiments.

To facilitate further investigation of the molecular mechanism underlying the regulatory effect of SirT1 on insulin-induced IRS-2 tyrosine phosphorylation, IRS-1- and IRS-2-coding sequences were PCR-amplified from mouse liver cDNA and were used to create expression constructs with N-terminal FLAG epitope. These DNA constructs were overexpressed in HEK293 cells (Fig. 3, B and C). The transfected cells were serum-starved overnight with or without coincubation of 6 mM nicotinamide and treated with insulin for 10 min. Consistent with the result in H4IIE cells, insulin treatment clearly led to potent tyrosine phosphorylations of both FLAG-IRS-1 and FLAG-IRS-2 proteins. However, although nicotinamide had minimal effect on insulin-induced IRS-1 tyrosine phosphorylation (Fig. 3B), it reduced insulin-induced tyrosine phosphorylation of IRS-2 protein significantly (Fig. 3C). Thus, FLAG-tagged IRS-2 in HEK293 cells responded similarly to nicotinamide treatment as endogenous IRS-2 protein.

View larger version (33K): [in this window] [in a new window]   FIGURE 3. Reduced SirT1 activity inhibits insulin-induced IRS-2 tyrosine phosphorylation. A, H4IIE cells transfected with pSIREN-Luciferase (stable control (SC) cells) or pSIREN-SirT1 (stable SirT1 (SS) cells) were serum-starved overnight before they were treated with and without 100 nM insulin for 10 min. IR, IRS-1, and IRS-2 protein were immunoprecipitated (IP) from total cell lysates using respective antibodies and analyzed by Western blot (WB) analysis. Half of the immunoprecipitates were used to measure the tyrosine phosphorylation levels (PY) of IR, IRS-1, and IRS-2 using a phosphotyrosine-specific antibody (4G10) from Millipore, whereas of the amount of the immunoprecipitates were used to measure the protein levels of IR, IRS-1, and IRS-2 by Western blot analysis. B and C, HEK293 cells were transfected with FLAG-IRS-1 (Fig. 3B) or FLAG-IRS-2 (Fig. 3C) and serum-starved overnight with and without co-treatment of 6 mM nicotinamide (NAM) before they were treated with insulin for 10 min. FLAG-tagged proteins (IRS-1 or IRS-2) were immunoprecipitated from total cell lysates using FLAG antibody and blotted with either phosphotyrosine-specific antibody (4G10) or FLAG antibody. Results are representatives of three independent experiments.

View larger version (42K): [in this window] [in a new window]   FIGURE 4. Localization of SirT1 and its interaction with IRS-2 protein. A, HEK293 cells were serum-starved overnight. Cell from two dishes were pooled together and fractionated as described under "Experimental Procedures," and one-sixth of total cytosol, nuclear, and membrane fractions were used for Western blot analysis using a SirT1 polyclonal antibody. As control, the localization of retinoblastoma protein (Rb), cAMP-responsive element binding protein 1 (CREB-1), and tubulin was also examined in equal portion using their respective antibodies. B, interaction of SirT1 and IRS-2 in transfected HEK293 cells. FLAG-tagged IRS-2 construct (0.5 µg/60-mm dish) was transfected to HEK293 cells with and without co-transfection of SirT1-Myc construct (0.5 µg/60 mm dish), as indicated in the figure. Cells were transfected for 48 h before they were serum-starved overnight and harvested for total cell lysates. Immunoprecipitation (IP) was performed using either FLAG or Myc monoclonal antibody and analyzed using FLAG and Myc antibodies, respectively. WB, Western blot. C, in vivo interaction of SirT1 and IRS-2 in HEK293 cells. HEK293 cells were serum-starved overnight. Cells from three dishes were pooled together for each treatment. Endogenous IRS-2 protein was immunoprecipitated using a polyclonal IRS-2 antibody, and normal rabbit IgG was used as negative control. The SirT1 protein level in half of the immunoprecipitate was analyzed by Western blot analysis using a polyclonal anti-SirT1 antibody from Santa Cruz. The IRS-2 protein level was also examined in 1/8 of total immunoprecipitate using polyclonal anti-IRS-2 antibody. D, IRS-1 interacted equally well with SirT1 as IRS-2. HEK293 cells were transfected with FLAG-IRS-1 or FLAG-IRS-2 with and without co-transfection of SirT1-Myc construct, as indicated in the figure. FLAG-IRS-1 and FLAG-IRS-2 were immunoprecipitated from total cell lysates using FLAG antibody. The immunoprecipitates were analyzed by Western blot analysis using Myc and FLAG antibody, respectively. The expression level of SirT1-myc was also analyzed in whole cell lysates (WCL) using Myc antibody.

To investigate the acetylation status of IRS-2 protein, FLAG-tagged IRS-2 protein was expressed in HEK293 cells (Fig. 5A) and serum-starved overnight with and without co-treatment of 10 mM nicotinamide. These cells were treated with insulin for 10 min and harvested for immunoprecipitation using monoclonal anti-FLAG antibody. Normal mouse IgG was used as negative control. Western blot analysis showed that immunoprecipitated FLAG-IRS-2 protein was acetylated at the basal level (compare lane 1 with lane 2), and treatment of insulin significantly reduced the acetylation level of FLAG-IRS-2 (compare lane 2 and lane 3). Treatment of nicotinamide overnight, on the other hand, prevented insulin-induced deacetylation of IRS-2 protein (compare lane 3 with lane 5). Next, endogenous IRS-2 protein was immunoprecipitated from H4IIE cells with and without insulin treatment using polyclonal anti-IRS-2 antibody alongside normal rabbit IgG as negative control. The acetylation status of IRS-2 protein was examined, and again, IRS-2 was acetylated at the basal level, and insulin treatment led to reduced acetylation level of IRS-2 protein. Overall, these results suggest that IRS-2 protein is acetylated at basal state, and its acetylation level is down-regulated by insulin.

Both IRS-1 and IRS-2 interacted equally well with SirT1. To understand why insulin-induced tyrosine phosphorylations of IRS-1 and IRS-2 responded differently to reduced SirT1 activity (Fig. 3), the acetylation status of IRS-1 was also examined alongside with that of IRS-2 in HEK293 cells using FLAG-tagged proteins (Fig. 5C). Consistent with previous results, FLAG-IRS-2 protein was acetylated at the basal level, and insulin treatment led to reduced acetylation level of FLAG-IRS-2. On the other hand, although the protein amount of IRS-1 is higher than that of IRS-2, the acetylation level of FLAG-IRS-1 protein was too low to be detected under the same conditions. Longer exposure showed that IRS-1 was weakly acetylated, and its acetylation was not regulated by insulin (data not shown). These results strongly suggest that insulin-induced IRS-2 deacetylation is accountable for the regulatory effect of SirT1 on insulin-induced IRS-2 tyrosine phosphorylation.

The direct involvement of SirT1 in insulin-induced IRS-2 deacetylation was also investigated in an in vitro deacetylation assay (Fig. 5D). FLAG-tagged IRS-2 protein was expressed in HEK293 cells and immunoprecipitated from total cell lysates using monoclonal anti-FLAG antibody. Endogenous SirT1 protein was also immunoprecipitated from insulin-treated HEK293 cells. The immunoprecipitated FLAG-IRS-2 protein and SirT1 protein were set up as indicated in Fig. 5D for 2 h at 37 °C, and the acetylation level of FLAG-IRS-2 protein was examined. The addition of SirT1 protein alone had a minimal effect on the acetylation level of FLAG-IRS-2 protein. However, the addition of SirT1 protein in the presence of 5 mM -NAD⁺ significantly reduced acetylation level of FLAG-IRS-2 to undetectable level under the same conditions (Fig. 5D, compare lane 3 with lane 4). This experiment suggests that IRS-2 protein may be a substrate of SirT1 protein deacetylase, and SirT1 is responsible for insulin-induced IRS-2 deacetylation in vivo.

View larger version (22K): [in this window] [in a new window]   FIGURE 5. Insulin-induced deacetylation of IRS-2 protein is critical to insulin-induced IRS-2 tyrosine phosphorylation. A, FLAG-IRS-2 acetylation was down-regulated by insulin. HEK293 cells were transfected with FLAG-IRS-2 and serum-starved overnight with and without co-incubation of 10 mM nicotinamide (NAM). Cells were treated with and without insulin for 10 min, and FLAG-IRS-2 protein was immunoprecipitated (IP) from total cell lysates by FLAG antibody. Mouse normal IgG was used as negative control. The acetylation level (Ac-K) of FLAG-IRS-2 protein was examined using monoclonal anti-Acetyl-Lysine antibody from Millipore (4G12). B, endogenous IRS-2 protein was acetylated at basal level. H4IIE cells were serum-starved overnight before they were treated with and without insulin for 10 min. Endogenous IRS-2 protein was immunoprecipitated from total cell lysates using a polyclonal IRS-2 antibody from Santa Cruz. The acetylation level (Ac-K) of immunoprecipitated IRS-2 protein was examined by Western blot analysis using monoclonal anti-acetyl-Lysine antibody from Millipore (4G12). Rabbit normal IgG was used as a negative control. C, comparison of the acetylation statuses of FLAG-IRS-1 and FLAG-IRS-2 protein. HEK293 cells were transfected with either FLAG-IRS-1 or FLAG-IRS-2 and serum-starved overnight before they were treated with and without insulin for 10 min. FLAG-IRS-1 and FLAG-IRS-2 were immunoprecipitated from total cell lysates using monoclonal FLAG antibody, and the acetylation levels (Ac-K) of FLAG-IRS-1 and FLAG-IRS-2 were examined by Western blot analysis using monoclonal anti-acetyl-lysine antibody (4G12). D, in vitro deacetylation of FLAG-IRS-2 protein by SirT1 protein. HEK293 cells were transfected with FLAG-IRS-2 and serum-starved overnight. FLAG-IRS-2 was immunoprecipitated using FLAG monoclonal antibody. Meanwhile, endogenous SirT1 protein was immunoprecipitated from insulin-treated HEK293 cells using a rabbit anti-SirT1 antibody. The in vitro reaction was set up as indicated in the figure and incubated at 37 °C for 2 h in a total volume of 200 µl. The agarose beads were centrifuged down and resuspended into sample buffer for Western blot analysis using antibodies against acetylated lysine (upper panel), SirT1 (middle panel), and FLAG epitope (lower panel). E, inhibition of SirT1 activity by RNAi inhibited insulin-induced deacetylation and tyrosine phosphorylation of IRS-2 protein. HEK293 stable clone carrying pSIREN-SirT1 (SirT1) or pSIREN-Luciferase (Luciferase) were transfected with FLAG-IRS-2 and serum-starved overnight before they were treated with insulin for 10 min. FLAG-IRS-2 was immunoprecipitated from total cell lysate. Its acetylation (Ac-K) and tyrosine phosphorylation levels (PY) were analyzed by Western blot analysis using antibody against tyrosine phosphorylation (4G10) or acetylated lysine (4G12). All the results are the representatives of at least three independent experiments.

The inverse relationship between IRS-2 acetylation and tyrosine phosphorylation indicates that one or more acetylated lysine residues in IRS-2 protein may be critical for SirT1 regulation of insulin-induced tyrosine phosphorylation of IRS-2. However, to identify these acetylation sites in IRS-2 protein may be difficult, since there is a total of 55 lysine residues in the IRS-2 coding sequence. On the other hand, considering the fact that nicotinamide significantly prevented insulin-induced deacetylation and tyrosine phosphorylation of IRS-2 protein (Fig. 3B), it is reasonable to assume that insulin-induced tyrosine phosphorylations of those IRS-2 fragments carrying putative acetylated lysine residues would be suppressed by nicotinamide. Therefore, a series of deletion mutants of FLAG-IRS-2 were created to narrow down IRS-2 fragment carrying these putative lysine residues. Using this method, the potential acetylation residues of IRS-2 was narrowed down to the first 590 amino acids of IRS-2 protein.

View larger version (19K): [in this window] [in a new window]   FIGURE 6. Identification of the critical lysine residues of IRS-2 in sirT1 regulation of insulin-induced IRS-2 tyrosine phosphorylation. A mutated FLAG-IRS-2 construct was created where four lysines at Lys-118/289/292/412 were mutated to alanines using site-directed mutagenesis and named FLAG-IRS-2 (K4A). This mutated construct was used alongside with FLAG-IRS-2 to transfect HEK293 cells, and the transfected cells were serum-starved overnight before they were treated with and without insulin (100 nM) for 10 min. Wild type (WT) and mutated proteins were immunoprecipitated (IP) using FLAG antibody, and their acetylation and tyrosine phosphorylation levels were analyzed by Western blot (WB 4G10) analysis using anti-acetyl-lysine (4G12) and anti-tyrosine phosphorylation antibodies.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
In this study reduced SirT1 deacetylase activity, either through direct inhibition or through reduced protein expression, led to reduced Akt activation and insulin-induced IRS-2 tyrosine phosphorylation; IRS-2 was acetylated at basal state, and the acetylation of IRS-2 was down-regulated by insulin; inhibition of SirT1 activity prevented insulin-induced IRS-2 deacetylation; an IRS-2 mutant was created where four lysine residues were mutated to alanine, and the basal level acetylation of this mutant protein was significantly inhibited along with its tyrosine phosphorylation upon insulin treatment. Based on these results, the underlying molecular mechanism of the regulatory effect of SirT1 on the insulin signaling pathway is proposed in Fig. 7. In this model insulin-induced tyrosine phosphorylation of insulin receptor and activation of SirT1 deacetylase are suggested to be two separate events in insulin signaling pathway. IRS-2 protein is acetylated at the basal state. Although insulin treatment leads to tyrosine phosphorylation of IR, which further recruits insulin receptor substrates including IRS-1 and IRS-2 to its kinase domain, the acetylated lysine residues in IRS-2 protein prevents IR kinase from further phosphorylating tyrosine residues in IRS-2 protein. Continuing phosphorylation of the tyrosine residues in IRS-2 protein requires removal of the acetyl group from acetylated lysine residues in IRS-2 protein by insulin-activated SirT1 protein deacetylase, and the phosphorylated IRS-2 protein then serves as an adaptor protein to further transmit insulin signaling to downstream targets. Undoubtedly, there are many unanswered questions in this model, and further experiments are required to fully vindicate or rectify this model. In addition, this model is based on cell culture studies. Animal studies are urgently needed to verify this model and to investigate its physiological significance.

View larger version (41K): [in this window] [in a new window]   FIGURE 7. Proposed model of SirT1 regulation of insulin-induced IRS-2 tyrosine phosphorylation. AC, acetyl group; Y, tyrosine residue; K, lysine residue; P, tyrosine phosphorylation.

Although the full impact of this regulation on overall energy homeostasis is still unclear, the physiological significance of this regulation has been suggested in several animal studies. The SirT1 protein level has been shown at a reduced level in mice subjected to high fat feeding (26) and in two aging models (27). Both aging and high fat-feeding are known to be associated with insulin resistance in vivo. Reduced SirT1 expression under these conditions through interfering with the insulin signaling pathway may directly cause or at least significantly contribute to overall insulin resistance in vivo.

Both the insulin signaling pathway and Sir2 family deacetylases have been tightly associated with aging, and there is some evidence suggesting that these two pathways may converge to regulate aging process in C. elegans. Overexpression of Sir2.1, the C. elegans counterpart of Sir2, significantly increases lifespan in C. elegans, and this effect is suppressed by mutation at Daf-16, the C. elegans homologue of forkhead proteins, and a key component of insulin signaling pathway (28). In a mammalian system, SirT1 is suggested to modulate insulin secretion in pancreas (4, 5), and it also directly regulates the transcriptional activity of forkhead proteins at the cellular level (13, 29). This study complements well with these reports, implying a common pathway through which both the insulin signaling pathway and Sir2 family deacetylases act on to regulate the aging process.

Although many components of the insulin signaling pathway have been demonstrated to be involved in the aging process ranging from C. elegans to mammals, the putative role of IRS proteins in this process is still unclear. There is little information about the role of IST-1 (C. elegans homologue of IRS protein) in the aging process (30). On the other hand, loss of Chico, the Drosophila homologue of IRS proteins, leads to significant lifespan extension (31). In the mammalian system, there is a family of four IRS proteins with divergent functions. The specific effect of SirT1 on IRS-2 tyrosine phosphorylation indicates that IRS-2 rather than other members of IRS family proteins may play critical role in the aging process.

This study also provides further insight into the molecular mechanism underlying the regulatory effect of SirT1 protein deacetylase on aging and other metabolic processes. The regulatory effect of Sir2 family protein deacetylases in the aging process has been well established in C. elegans, yeast, and Drosophila (2). However, the molecular mechanism underlying this regulation is still unclear. The identification of IRS-2 as another putative substrate of SirT1 suggests that SirT1 may also be through regulating IRS-2-mediated signaling pathway to control aging and other biological processes.

In fact, animal models with genetically mutated SirT1 and IRS-2 genes strongly support this hypothesis (32, 33). The female null mice of both IRS-2 and SirT1 showed smaller ovaries with very few follicles and reduced luteinizing hormone, prolactin, and sex steroids (33, 34). The remarkable similar phenotypes in female infertility between SirT1 and IRS-2 null mice strongly imply an intrinsic connection between SirT1 and IRS-2-mediated signaling pathway in female reproductivity.

One unexpected observation in this study is the cytosolic localization of SirT1 protein. SirT1 protein has been demonstrated as a nuclear protein (35). However, this study relied heavily on fluorescence microscopy technique. Although this technique can convincingly demonstrate the presence of SirT1 protein in nucleus, it cannot rule out the presence of this protein in cytosol. Furthermore, the presence of SirT1 protein in cytosol was also suggested in several other studies, including the phosphatidylinositol 3-kinase regulation of nucleocytoplasmic shuttling of SirT1 protein (36) and the putative SirT1 deacetylation of Acetyl-CoA synthase, a known cytosolic protein (21).

In addition, this study also reveals useful information about the signaling pathway leading to the activation of MAPK and Akt kinases. MAPK and Akt kinase cascades are important components of insulin signaling pathway, mediating a variety of downstream events. In this study reduced IRS-2 tyrosine phosphorylation in cells with impaired SirT1 activity led to significantly reduced Akt activation yet had minimal effect on MAPK activation, suggesting that IRS-2 tyrosine phosphorylation may be exclusively linked with Akt activation in these cells. This conclusion is consistent with a study where mouse ovaries from wild type and IRS-2 null mice were used. Compared with that of wild type mice, insulin-induced Akt activation was significantly attenuated in IRS-2 null mice, whereas insulin-induced MAPK activation was minimally affected (37). However, in other studies, reduced IRS-2 protein levels through RNAi led to diverse effects on AKT and MAPK activations, including appreciable increased Akt activation in mouse liver (38) or reduced activations of both MAPK and Akt kinases in muscle cells (39, 40). The molecular mechanism underlying these discrepancies is still unclear. The probable explanations may include tissue specificity and that fact that in this study the overall tyrosine phosphorylation level rather than the protein level of IRS-2 protein was significantly reduced.

In summary, the current study suggests that SirT1 protein may, through regulation of the acetylation level of IRS-2 protein, directly regulate insulin-induced IRS-2 tyrosine phosphorylation and its downstream Akt activation. This study also suggests that deacetylation of IRS-2 protein is a critical component of insulin-induced IRS-2 tyrosine phosphorylation. The identification of a novel regulatory step in insulin-induced IRS-2 tyrosine phosphorylation and the novel role of SirT1 in regulation of insulin signaling pathway also have direct implications in our understanding of aging, diabetes, and other metabolic processes associated with insulin signaling pathway.

	FOOTNOTES

 
^* This work was supported by the Center for Human Nutrition Endowment and the Moss Heart Center, University of Texas Southwestern Medical Center at Dallas, TX. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.

¹ To whom correspondence should be addressed: Rigel Pharmaceutical Co., 1180 Veterans Blvd., South San Francisco, CA 94080. Tel.: 650-624-1105; E-mail: jiandi.zhang{at}gmail.com.

² The abbreviations used are: IRS-1, insulin receptor (IR) substrate 1; RNAi, RNA interference; SC cells, stable control cells; SS cells, stable SirT1 cells; Luc, luciferase; MAPK, mitogen-activated protein kinase.

	ACKNOWLEDGMENTS

 
I thank Dr. Scott Grundy (University of Texas Southwestern Medical Center) for constant support and Dr. Mike Brown (University of Texas Southwestern Medical Center) for support and invaluable advice.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Fontana, L., Meyer, T. E., Klein, S., and Holloszy, J. O. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 6659-6663[Abstract/Free Full Text]
2. Blander, G., and Guarente, L. (2004) Annu. Rev. Biochem. 73, 417-435[CrossRef][Medline] [Order article via Infotrieve]
3. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., and Puigserver, P. (2005) Nature 434, 113-118[CrossRef][Medline] [Order article via Infotrieve]
4. Bordone, L., Motta, M. C., Picard, F., Robinson, A., Jhala, U. S., Apfeld, J., McDonagh, T., Lemieux, M., McBurney, M., Szilvasi, A., Easlon, E. J., Lin, S. J., and Guarente, L. (2006) PLoS Biol. 4, e31[CrossRef][Medline] [Order article via Infotrieve]
5. Moynihan, K. A., Grimm, A. A., Plueger, M. M., Bernal-Mizrachi, E., Ford, E., Cras-Meneur, C., Permutt, M. A., and Imai, S. (2005) Cell Metab. 2, 105-117[CrossRef][Medline] [Order article via Infotrieve]
6. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Oliveira, R. M., Leid, M., McBurney, M. W., and Guarente, L. (2004) Nature 429, 771-776[CrossRef][Medline] [Order article via Infotrieve]
7. Tatar, M., Bartke, A., and Antebi, A. (2003) Science 299, 1346-1351[Abstract/Free Full Text]
8. Kahn, C. R., Vicent, D., and Doria, A. (1996) Annu. Rev. Med. 47, 509-531[CrossRef][Medline] [Order article via Infotrieve]
9. Bluher, M., Kahn, B. B., and Kahn, C. R. (2003) Science 299, 572-574[Abstract/Free Full Text]
10. Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., Shimomura, I., Takayama, Y., Herz, J., Kahn, C. R., Rosenblatt, K. P., and Kuro-o, M. (2005) Science 309, 1829-1833[Abstract/Free Full Text]
11. Zhang, J. (2006) Biochem. J. 397, 519-527[CrossRef][Medline] [Order article via Infotrieve]
12. Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., and Sinclair, D. A. (2002) J. Biol. Chem. 277, 45099-45107[Abstract/Free Full Text]
13. Motta, M. C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma, Y., McBurney, M., and Guarente, L. (2004) Cell 116, 551-563[CrossRef][Medline] [Order article via Infotrieve]
14. Inoue, G., Cheatham, B., Emkey, R., and Kahn, C. R. (1998) J. Biol. Chem. 273, 11548-11555[Abstract/Free Full Text]
15. Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., and Mayo, M. W. (2004) EMBO J. 23, 2369-2380[CrossRef][Medline] [Order article via Infotrieve]
16. Nemoto, S., Fergusson, M. M., and Finkel, T. (2004) Science 306, 2105-2108[Abstract/Free Full Text]
17. Nemoto, S., Fergusson, M. M., and Finkel, T. (2005) J. Biol. Chem. 280, 16456-16460[Abstract/Free Full Text]
18. Pagans, S., Pedal, A., North, B. J., Kaehlcke, K., Marshall, B. L., Dorr, A., Hetzer-Egger, C., Henklein, P., Frye, R., McBurney, M. W., Hruby, H., Jung, M., Verdin, E., and Ott, M. (2005) PLoS Biol. 3, e41[CrossRef][Medline] [Order article via Infotrieve]
19. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. (2001) Cell 107, 137-148[CrossRef][Medline] [Order article via Infotrieve]
20. Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Frye, R. A., Pandita, T. K., Guarente, L., and Weinberg, R. A. (2001) Cell 107, 149-159[CrossRef][Medline] [Order article via Infotrieve]
21. Hallows, W. C., Lee, S., and Denu, J. M. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 10230-10235[Abstract/Free Full Text]
22. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve]
23. Wong, S., and Weber, J. D. (2007) Biochem. J. 407, 451-460[CrossRef][Medline] [Order article via Infotrieve]
24. Rui, L., Fisher, T. L., Thomas, J., and White, M. F. (2001) J. Biol. Chem. 276, 40362-40367[Abstract/Free Full Text]
25. Kerouz, N. J., Horsch, D., Pons, S., and Kahn, C. R. (1997) J. Clin. Investig. 100, 3164-3172[Medline] [Order article via Infotrieve]
26. Deng, X. Q., Chen, L. L., and Li, N. X. (2007) Liver Int. 27, 708-715[CrossRef][Medline] [Order article via Infotrieve]
27. Sommer, M., Poliak, N., Upadhyay, S., Ratovitski, E., Nelkin, B. D., Donehower, L. A., and Sidransky, D. (2006) Cell Cycle 5, 2005-2011[Medline] [Order article via Infotrieve]
28. Tissenbaum, H. A., and Guarente, L. (2001) Nature 410, 227-230[CrossRef][Medline] [Order article via Infotrieve]
29. Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., Hu, L. S., Cheng, H. L., Jedrychowski, M. P., Gygi, S. P., Sinclair, D. A., Alt, F. W., and Greenberg, M. E. (2004) Science 303, 2011-2015[Abstract/Free Full Text]
30. Wolkow, C. A., Munoz, M. J., Riddle, D. L., and Ruvkun, G. (2002) J. Biol. Chem. 277, 49591-49597[Abstract/Free Full Text]
31. Clancy, D. J., Gems, D., Harshman, L. G., Oldham, S., Stocker, H., Hafen, E., Leevers, S. J., and Partridge, L. (2001) Science 292, 104-106[Abstract/Free Full Text]
32. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., Bonner-Weir, S., and White, M. F. (1998) Nature 391, 900-904[CrossRef][Medline] [Order article via Infotrieve]
33. McBurney, M. W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., Webb, J. R., Lansdorp, P. M., and Lemieux, M. (2003) Mol. Cell. Biol. 23, 38-54[Abstract/Free Full Text]
34. Burks, D. J., Font de Mora, J., Schubert, M., Withers, D. J., Myers, M. G., Towery, H. H., Altamuro, S. L., Flint, C. L., and White, M. F. (2000) Nature 407, 377-382[CrossRef][Medline] [Order article via Infotrieve]
35. Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. (2004) Mol. Cell 16, 93-105[CrossRef][Medline] [Order article via Infotrieve]
36. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2006) J. Biol. Chem. 282, 6823-6832[CrossRef][Medline] [Order article via Infotrieve]
37. Neganova, I., Al-Qassab, H., Heffron, H., Selman, C., Choudhury, A. I., Lingard, S. J., Diakonov, I., Patterson, M., Ghatei, M., Bloom, S. R., Franks, S., Huhtaniemi, I., Hardy, K., and Withers, D. J. (2007) Biol. Reprod. 76, 1045-1053[Abstract/Free Full Text]
38. Taniguchi, C. M., Ueki, K., and Kahn, R. (2005) J. Clin. Investig. 115, 718-727[CrossRef][Medline] [Order article via Infotrieve]
39. Bouzakri, K., Zachrisson, A., Al-Khalili, L., Zhang, B. B., Koistinen, H. A., Krook, A., and Zierath, J. R. (2006) Cell Metab. 4, 89-96[CrossRef][Medline] [Order article via Infotrieve]
40. Dong, X., Park, S., Lin, X., Copps, K., Yi, X., and White, M. F. (2006) J. Clin. Investig. 116, 101-114[CrossRef][Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J.-H. Lee, M.-Y. Song, E.-K. Song, E.-K. Kim, W. S. Moon, M.-K. Han, J.-W. Park, K.-B. Kwon, and B.-H. Park Overexpression of SIRT1 Protects Pancreatic {beta}-Cells Against Cytokine Toxicity by Suppressing the Nuclear Factor-{kappa}B Signaling Pathway Diabetes, February 1, 2009; 58(2): 344 - 351. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplemental Data All Versions of this Article: 282/47/34356    most recent M706644200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Social Bookmarking                      What's this?